Drug Trial Radar · NCT07168473
Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma
Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
274
Planned (sponsor's estimate)
Start
Sep 9, 2024
Primary completion
Aug 31, 2026
Study completion Sep 18, 2026
Sponsor
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to compare the efficacy and safety of DW1807 and DW1807-R2 in patients with perennial allergic rhinitis and comorbid asthma. The primary objective is to demonstrate the superiority of DW1807 over DW1807-R2 in improving the reflective total nasal symptom score (rTNSS) after 4 weeks of treatment.
Conditions
- Perennial Allergic Rhinitis Accompanied by Asthma
Interventions
ExperimentalDrug
1. DW1807 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks 2. DW1807-R2 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks
ComparatorDrug
1. DW1807 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks 2. DW1807-R2 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean change in reflective Total Nasal Symptom Score (rTNSS)Time frame: During the last 2 weeks of the treatment period (i.e., Weeks 3 to 4 of investigational product administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Konkuk University Medical Center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.